CervoMed Inc. Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss
CervoMed Inc. (CRVO) reported Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$35.64 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2023-03-24
- CervoMed Inc. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was -$35.64K.
| Period end | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|
| 2022-12-31 | -$35.64K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |